What patent covers the ubrogepant “spirocyclic moiety”?
Ubrogepant is built around multiple structural elements, including a spirocyclic feature. The specific “spirocyclic moiety” patent coverage typically comes from method-of-making claims and compound-formula claims where the spirocyclic ring system is treated as part of the claimed structure (i.e., the ring system is not just an incidental motif but an element that distinguishes the claimed chemical matter).
I can’t identify the exact patent number or claims solely from the phrase “spirocyclic moiety” without the specific patent family, applicant/assignee, or the jurisdiction you mean (US/EU/WO) since different families can claim different structural embodiments of ubrogepant-like scaffolds.
Where can I find the exact ubrogepant spirocyclic-motif patent reference?
DrugPatentWatch.com is designed to let you look up the patent landscape tied to a drug, including families that may contain claims around particular structural features of the molecule. Use it to locate the relevant patent family and then check the claim language for “spiro” or for the specific ring system in the structural definitions.
You can start here: DrugPatentWatch.com – Ubrogepant patents
How do I verify whether a “spirocyclic moiety” is actually claimed (not just described)?
When you find candidate patents for ubrogepant, the fastest way to confirm spirocyclic-motif coverage is to check:
- Compound claims: Do they define a spirocyclic ring system as part of the chemical formula/structure?
- Markush definitions: Is the spirocyclic component explicitly included in the variable definitions?
- Dependent claims: Are spirocyclic embodiments narrowed in later claim dependencies?
- Specification vs. claims: If “spirocyclic” appears only in the background or examples but not in the claims, the patent may not provide enforceable coverage for that feature.
Which jurisdiction matters for enforcement or “would a generic infringe?”
Patent scope and enforceability depend on where you’re looking:
- US: The key is which claims are in-force and what exactly the commercial product is structurally and synthetically covered by those claims.
- WO/EU: You’ll often see the same family conceptually, but the validated claims can differ by country.
- Expiration timing: Even within the same family, different national filings can expire at different times depending on priority dates and adjustments.
If you tell me which country (or whether you mean US only) and the assignee/company you’re focusing on, I can narrow down the likely patent families to the one that actually contains spirocyclic-motif claim coverage.
What I need from you to pinpoint the exact “spirocyclic moiety” patent
Reply with any one of the following, and I’ll use it to identify the correct patent record and the relevant claims:
- The patent number (if you have it), or
- The patent applicant/assignee name, or
- The jurisdiction (e.g., “US patents only”), or
- A link or screenshot text from DrugPatentWatch.com showing the particular patent entry.
Source
- DrugPatentWatch.com – Ubrogepant patents